Atorvastatin transport in the Caco-2 cell model: Contributions of P- glycoprotein and the proton-monocarboxylic acid co-transporter

Pharmaceutical Research

Volumn 17, Issue 2, 2000, Pages 209-215

  Wu, Xiaochun ^a,b   Whitfield, Lloyd R ^a   Stewart, Barbra H ^a  

^a PFIZER INC   (United States)

^b Cerep Inc   (United States)

Author keywords

Atorvastatin; Caco 2; Monocarboxylic acid transporter; P glycoprotein

Indexed keywords

ATORVASTATIN; CARBOXYLIC ACID DERIVATIVE; CYCLOSPORIN A; GLYCOPROTEIN P; VERAPAMIL; VINBLASTINE;

ARTICLE; CELL STRAIN CACO 2; DRUG ELIMINATION; DRUG MECHANISM; DRUG PENETRATION; DRUG TRANSPORT; HUMAN; HUMAN CELL; ISOTOPE LABELING; MONOLAYER CULTURE; PH MEASUREMENT; PRIORITY JOURNAL;

ACETIC ACID; ANION TRANSPORT PROTEINS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BENZOIC ACID; BIOLOGICAL TRANSPORT; CACO-2 CELLS; CALCIUM CHANNEL BLOCKERS; CARBON RADIOISOTOPES; CARBONYL CYANIDE P-TRIFLUOROMETHOXYPHENYLHYDRAZONE; CARBOXYLIC ACIDS; CARRIER PROTEINS; CELL POLARITY; CYCLOSPORINE; DRUG INTERACTIONS; HEPTANOIC ACIDS; HUMANS; HYDROGEN-ION CONCENTRATION; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; IMMUNOSUPPRESSIVE AGENTS; INDICATORS AND REAGENTS; IONOPHORES; NIACIN; P-GLYCOPROTEIN; PROTONS; PYRROLES; VERAPAMIL; VINBLASTINE;

EID: 0034059327     PISSN: 07248741     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1007525616017     Document Type: Article

References (15)

1. 1. D. D. Cilla, Jr., L. R. Whitfield, D. M. Gibson, A. J. Sedman, and E. L. Posvar. Multiple-dose pharmacokinetics, pharmacodynamics, and safety of atorvastatin, an inhibitor of HMG-CoA reductase, in healthy subjects. Clin. Pharmacol. Ther. 60, 687-695 (1996).
2. 2. D. M. Gibson, R. H. Stern, R. B. Able, and L. R. Whitfield. Absolute bioavailability of atorvastatin in man, Pharm. Res. 14 (Suppl):S-253 (1997).
3. 3. B. M. Michniewicz, A. E. Black, M. W. Sinz, and T. F. Woolf. In vitro and in vivo metabolism of atorvastatin (CI-981). ISSX Proceeding, Volume 6, p 93, Sixth North American ISSX Meeting, Raleigh, NC, Oct 23-27 (1994).
4. 3H-digoxin in Caco-2 cell monolayers. Pharm. Res. 14 (Suppl):S-671 (1997).
5. 5. J. Dimitroulakos and H. Yeger. HMG-CoA reductase mediates the biological effects of retinoic acid on human neuroblastoma cells. Nature Med. 2, 326-333 (1996).
6. 6. A. Tsuji, H. Takanaga, I. Tamai, and T. Terasaki. Transcellular transport of benzoic acid across Caco-2 cells by a pH-dependent and carrier-mediated transport mechanism. Pharm. Res. 11:30-37 (1994).
7. 7. I. Tamai, H. Takanaga, H. Maeda, T. Ogihara, M. Yoneda, and A. Tsuji. Proton-co-transport of pravastatin across intestinal brush-border membrane. Pharm. Res. 12:1727-1732 (1995).
8. rd ed. pp332-467, Academic Press (1979).
9. 9. J. Hunter, M. A. Jepson, T. Tsuruo, N. L. Simmons, and B. H. Hirst. Functional expression of P-glycoprotein in apical membranes of human intestinal Caco-2 cells. J. Biol. Chem. 268:14991-14997 (1993).
10. 10. E. B. Mechetner and I. B. Roninson. Efficient inhibition of P-glycoprotein-mediated multidrug resistance with a monoclonal antibody. Proc. Natl. Acad. Sci. USA 89:5824-5828 (1992).
11. 11. H. Gutmann, G. Fricker, M. Török, S. Michael, C. Beglinger, and J. Drewe. Evidence for different ABC-transporters in Caco-2 cells modulating drug uptake. Pharm. Res. 16:402-407 (1999).
12. 12. U. K. Walle, K. I. French, R. A. Walgren, and T. Walle. Transport of genitein-7-glucoside by human intestinal Caco-2 cells: potential role for MRP2. Res. Commun. Mol. Pathol. Pharmacol 103:45-56 (1999).
13. 13. I. Tamai, H. Takanaga, H. Maeda, Y. Sai, T. Ogihara, H. Higashida, and A. Tsuji. Participation of a proton-cotransporter, MCT1 in the intestinal transport mechanism for monocarboxylic acids. Biochem. Biophys. Res. Commun. 214:482-489 (1995).
14. 14. A. Tsuji and I. Tamai. Carrier-mediated intestinal transport of drugs. Pharm Res. 13:963-977 (1996).
15. 15. B.-B. Yang, J. A. Smithers, R. H. Stern, A. J. Sedman, and S. C. Olson, Pharmacokinetics and dose proportionality of atorvastatin and its active metabolites. Pharm. Res. 13 (Suppl):S-437 (1996).